Hydroxychloroquine is the most controversial of all experimental drugs used in COVID-19 therapy,media BGR reported. From the moment the first study showed the drug might be effective, U.S. President Donald Trump has advocated the use of hydroxychloroquine to treat the new coronavirus. When the larger study highlighted that taking the antimalarial drug could cause severe heart side effects in PATIENTs with COVID-19, he later announced that he had stopped taking the drug.
Since then, we have seen a broad study of nearly 100,000 COVID-19 patients, concluding that hydroxychloroquine is more likely to lead to serious health problems than to provide any benefits for new corona patients. The World Health Organization (WHO) stopped its research on hydroxychloroquine earlier this week, and France and other EU countries followed suit. But Mr. Trump said he would still take the drug if he was infected, even if there was no evidence it was effective.
According to Capitol Hill, Trump told White House Press Secretary Kayleigh McNany that he felt “perfect” after receiving hydroxychloroquine treatment, the Capitol Hill newspaper reported. “He felt absolutely great after taking the treatment,” Mr McNerney said. McNerney spoke to Trump about the drug before Thursday’s briefing, and the president told her that he “would take it again if he thought he had been exposed to new coronary pneumonia.”
Mr. Trump said last week that he was taking hydroxychloroquine as a precaution, although there was no evidence that the special treatment could prevent the new coronavirus infection. Americans should consult a doctor when considering taking the drug, mcNally said at the briefing. But she said hydroxychloroquine has been approved for non-labeled use and that it is safe for other conditions.
“There’s a lot of exaggeration that this is unsafe. I’ve seen some of the things that’s been reported out there—- there are consequences of stopping people from being recruited in actual clinical trials. McNerney said. “It is important to note that this drug has been safely used by millions of people for a long time. “
As it turns out, some Americans have taken this to account and have bought a lot of drugs in the past few months. A new Brigham and Women’s Hospital study compared the same 10-week prescriptions for hydroxychloroquine and other commonly used prescription drugs in 2019 and 2020. Not surprisingly, the amount of oxychloroquine prescribed has skyrocketed, as can be seen in the figures above and below.
“There are already indications of an increase in the amount of oxychloroquine prescriptions and reports of shortages, but this study will focus on the extent to which overdoses of oxychloroquine/chloroquine prescriptions are filled nationwide,” study author Dr. Haider Warraich told MedicalXpress. “This analysis does not include patients who have been prescribed HCQ in hospitals — meaning that patients may be taking medication at home without monitoring or monitoring side effects. “
The team looked at prescriptions between February 16 and April 25 and found that the filling of all the drugs they looked at peaked in the week from March 15 to March 21, 2020. Trump declared a state of emergency in the United States on March 13. On March 17, the first hydroxychloroquine study appeared in a preprint, and Trump approved the drug on March 19.
The team found that the number of prescriptions for 28 tablets of oxychloroquine/chloroquine increased from 2,208 prescriptions in 2019 to 45,858 orders in 2020. That was a 1977% increase. Over the 10-week period, there were 483,425 excess hydroxychloroquine fills compared to the same period last year. There was also a shortage of hydroxychloroquine in patients who were really needed.
“During this pandemic, information about the benefits and potential harms of commonly used drugs such as oxychloroquine was both good and misinformed, and there was speculation that proven drugs to treat heart failure might be harmful to this segment of the patient population,” Warraich said. “A positive finding is that we have not seen a dramatic reduction in prescription filling for routine, chronic care, but our results on hydroxychloroquine are worrying. “